ClinicalTrials.gg
Not yet recruitingNCT07863050BLOSSOMUpdated Oct 13, 2026

Unflavored Powdered Multivitamin in Children

An interventional study of EllaOla Kids Essentials Unflavored Powdered Multivitamin and Placebo (Tapioca Fiber) in Selective Eating, Emotional Dysregulation and Child Behavior, sponsored by EllaOla. Not yet recruiting. Open to participants aged 4 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by EllaOla · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 13, 2026Title changedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
4 Years to 11 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether a daily unflavored powdered multivitamin (EllaOla Kids Essentials) improves mood and behavior in children aged 4 to 11 who are picky eaters and experience behavioral challenges. Researchers will also look at whether the multivitamin affects overall health, well-being, nutrition, and serum vitamin levels, and whether it is safe and well tolerated.

The main questions it aims to answer are:

Do more parents of children taking the multivitamin report a clinically meaningful improvement in their child's overall mood and behavior after 12 weeks than parents of children taking a placebo? Does the multivitamin change parent-reported emotional reactivity, overall health and well-being, and nutrition over 12 weeks? In children who take part in optional at-home blood testing, does the multivitamin improve serum vitamin D and vitamin B12 levels?

Researchers will compare the multivitamin to a placebo (a look-alike powder made of tapioca fiber that contains no vitamins) to see if it improves mood and behavior.

Participants will:

Be randomly assigned to receive either the multivitamin or the placebo. Neither the families nor the study team will know which one the child gets.

Have a parent or caregiver mix the powder into the child's food or drink once a day at home for 12 weeks.

Have a parent or caregiver complete short online questionnaires about the child's mood, behavior, health, and nutrition at baseline and at Weeks 2, 4, 6, 8, and 12, using a smartphone app. All study visits are remote.

Choose whether to do an optional at-home blood collection at the start and at Week 12.

Choose whether to continue in an optional 12-week open-label extension (Weeks 12-24), where all children, including those who were on placebo, receive the multivitamin.

02

Conditions studied

  • Selective Eating
  • Emotional Dysregulation
  • Child Behavior
  • Healthy Children (Wellness Study)

Keywords

  • Multivitamin
  • Dietary Supplement
  • Micronutrients
  • Pediatric Nutrition
  • Mood and Behavior
  • Vitamin D
  • Vitamin B12
  • Decentralized Clinical Trial
  • Placebo Controlled
03

In context

Child Behavior

224 studies on the registry are indexed under Child Behavior; 39 are open to participants now.

This study's planned enrollment of 166 is above the median of 140 across 197 interventional studies indexed under Child Behavior.

Browse Child Behavior studies →

Lead sponsor

This is the only study on the registry with EllaOla as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy child aged 4-11 years at time of enrollment, male or female
  2. Not currently taking oral over-the-counter supplements or another multivitamin, if they are taking, must discontinue use for at least four weeks prior to randomization and for the duration of the study.
  3. Parent reports active concern/challenge in behavior and selective eating confirmed by minimum threshold scores on three screening instruments: a. Selective Eating: \</= 3 on the Selective Eating Screening Tool Section A and at least two behavioral anchors Q11 = concern about child's nutrition "3-4 days per week or 5-7 days per week), Q12 = "fewer than 20 foods" (10-19 or fewer than 10), Q13 = refusal of ≥ 1 whole food group b. Behavior: Participants must meet both of the following criteria: 1. EDI Reactivity T-score ≥ 60 (for EDI or EDI-YC dependent on age of child); indicating elevated emotional reactivity relative to age-based norms (general population norms); -AND- 2. Behavioral Screening Tool: Evidence of baseline difficulty in behavior and emotional regulation, defined as: ○ A rating of "Often" or "Very Often" (score ≥ 4) on all three Mood and Behavior Difficulties screening items;
  4. Generally healthy as determined by caregiver report without any chronic medical condition that is unstable is actively being treated with medication changes, or that in the judgment of the Investigator would interfere with study participation or interpretation of results.
  5. Parent is willing and able to administer the study product daily and complete questionnaires at all timepoints
  6. Willing and able to maintain current diet, physical activity consistently throughout the study duration.
  7. Parent is able to read and understand English.
  8. Parent is able to read, understand, and provide .
  9. Parent is able to use a personal smartphone device and download Chloe by People Science.
  10. Able to receive shipment of the product at an address within the United States.
  11. Parent is able to complete study assessments over the course of up to 20 weeks.

Exclusion criteria

Exclusion Criteria:

Any potential participants who:

  1. Parent does not have a personal smartphone, internet access, or is unwilling to download Chloe.
  2. Child does not meet minimum threshold screening scores in two domains as specified in Inclusion Criteria 3
  3. Concomitant Therapies:

    1. Current use of stimulant medication, antipsychotics, or appetite-modifying medications that has been initiated or changed within 8 weeks prior to enrollment (stable, long-term use may be considered on a case-by-case basis with Investigator approval).
    2. Current use of any medication, supplement, or herbal remedy specifically targeted at behavior or appetite that has been initiated or changed within 8 weeks prior to randomization, or that the caregiver is unwilling to keep stable and unchanged for the duration of the study
    3. Participants receiving any therapies or treatments within 30 days prior to randomization.
    4. Caregiver intends to introduce any new medications, supplements, or herbal remedies targeting behavior or appetite during the study period.
  4. Other Illnesses or Conditions:

    1. Diagnosed psychiatric disorders including but not limited to major depressive disorder, bipolar disorder, psychotic disorders or severe anxiety requiring medication changes or intensive treatment
    2. Hospitalization or significant acute illness within 3 months prior to randomization that, in the judgment of the Investigator, could affect study outcomes or participant safety.
    3. Planned major surgery or invasive treatment during study duration that, in the judgment of the principal investigator, would interfere with study participation or interpretation of results.
  5. Known allergies or to any of the study or placebo product ingredients
  6. Currently enrolled in another interventional research study or plans to enroll in any other interventional research study at any point during the study's duration

    a. Only one child per household may enroll in this research at a time

  7. Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (estimated)

Study arms

  • Experimental
    Arm 1 - Experimental: EllaOla Kids Essentials Multivitamin

    Participants receive EllaOla Kids Essentials Unflavored Powdered Multivitamin, administered daily at home by the parent/caregiver for 12 weeks (double-blind core period). Participants may opt into a 12-week open-label extension (Weeks 12-24) and continue receiving the active multivitamin.

    Dietary Supplement: EllaOla Kids Essentials Unflavored Powdered Multivitamin

  • Placebo comparator
    Arm 2 - Placebo Comparator: Placebo (Tapioca Fiber)

    Participants receive a matching placebo (tapioca fiber) of identical appearance, administered daily at home by the parent/caregiver for 12 weeks (double-blind core period). Participants may opt into a 12-week open-label extension (Weeks 12-24) and switch to the active multivitamin (delayed start).

    Dietary Supplement: Placebo (Tapioca Fiber)

Interventions

  • Dietary supplementEllaOla Kids Essentials Unflavored Powdered Multivitamin

    An unflavored, powdered children's multivitamin. Each serving provides vitamins A, C, D3 (20 mcg), E, K2, B1, B3, B5, B6, B12 (2 mcg), folate, and biotin, plus iodine, zinc, selenium, manganese, and a fruit and vegetable blend, in a tapioca fiber base with monk fruit. Parents/caregivers give one full serving once daily in the morning, mixed into at least 2 ounces of juice or milk, for 12 weeks. Participants who opt into the open-label extension continue daily use through Week 24.

    Also known as: EllaOla Kids Essentials, Study Product

  • Dietary supplementPlacebo (Tapioca Fiber)

    A tapioca fiber powder with no vitamins or minerals, matched to the study product in appearance, packaging, and labeling. Parents/caregivers give one full serving once daily in the morning, mixed into at least 2 ounces of juice or milk, for the 12-week double-blind period. Used as Placebo comparator only.

    Also known as: Matching Placebo

06

What researchers measure

Primary outcomes

  1. Proportion of PGI-C Responders on the Overall Mood and Behavior Item

    Proportion of participants rated by their parent/caregiver as "very much improved" (1) or "much improved" (2) on the Overall Mood and Behavior item of the Parent Global Impression of Change (PGI-C). The PGI-C is rated on a 7-point scale (1 = very much improved; 4 = no change; 7 = very much worse). Lower scores indicate greater improvement.

    Time frame: Week 12

Secondary outcomes

  1. Proportion of PGI-C Responders on the Overall Mood and Behavior Item Over Time

    Proportion of participants rated "very much improved" (1) or "much improved" (2) on the PGI-C Overall Mood and Behavior item. The 7-point scale runs from 1 = very much improved to 7 = very much worse, with 4 = no change.

    Time frame: Weeks 2, 4, 6, 8, and 12

  2. Proportion of PGI-C Improvers on the Overall Mood and Behavior Item

    Proportion of participants rated "very much improved" (1), "much improved" (2), or "minimally improved" (3) on the PGI-C Overall Mood and Behavior item. The 7-point scale runs from 1 = very much improved to 7 = very much worse, with 4 = no change.

    Time frame: Weeks 2, 4, 6, 8, and 12

  3. Mean PGI-C Overall Mood and Behavior Score

    Mean parent-rated score on the PGI-C Overall Mood and Behavior item. The 7-point scale runs from 1 = very much improved to 7 = very much worse, with 4 = no change. Lower scores indicate greater improvement.

    Time frame: Weeks 2, 4, 6, 8, and 12

  4. Change From Baseline in Serum 25-Hydroxyvitamin D [25(OH)D] (Blood Work Subgroup)

    Change from baseline in serum 25(OH)D in the optional blood work subgroup. Samples are collected at home with the Tasso Mini device.

    Time frame: Baseline and Week 12

  5. Change From Baseline in Serum Vitamin B12 (Blood Work Subgroup)

    Change from baseline in serum vitamin B12 in the optional blood work subgroup. Samples are collected at home with the Tasso Mini device.

    Time frame: Baseline and Week 12

  6. PGI-C Overall Health and Well-being: Responder Proportion and Mean Score

    Proportion of participants rated "very much improved" (1) or "much improved" (2), and the mean score, on the PGI-C Overall Health and Well-being item. The 7-point scale runs from 1 = very much improved to 7 = very much worse, with 4 = no change. Lower scores indicate greater improvement.

    Time frame: Weeks 2, 4, 6, 8, and 12

  7. PGI-C Overall Nutrition: Responder Proportion and Mean Score

    Proportion of participants rated "very much improved" (1) or "much improved" (2), and the mean score, on the PGI-C Overall Nutrition item. The 7-point scale runs from 1 = very much improved to 7 = very much worse, with 4 = no change. Lower scores indicate greater improvement.

    Time frame: Weeks 2, 4, 6, 8, and 12

  8. PGI-C Mood and Behavior Domain Composite Score

    Mean of the two PGI-C Mood and Behavior domain items (tantrums/meltdowns and mood), along with the individual item scores. Each item is rated on a 7-point scale from 1 = very much improved to 7 = very much worse, with 4 = no change. Lower scores indicate greater improvement.

    Time frame: Weeks 2, 4, 6, 8, and 12

  9. Change From Baseline in Emotion Dysregulation Inventory (EDI) Reactivity Score

    Change from baseline in the parent-reported EDI Reactivity Index score. The EDI-Young Child is used for ages 4-5 and the standard EDI for ages 6-11. Items are rated on a 5-point scale (0 = not at all to 4 = very severe) over the past 7 days. Higher scores indicate poorer emotion regulation.

    Time frame: Baseline, Weeks 4, 8, and 12

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.

Of 141 interventional studies with no phase under Child Behavior, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 41. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartEst.
Oct 14, 2026
Primary completionEst.
Mar 20, 2027
CompletionEst.
May 19, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of an Unflavored Powdered Multivitamin on Behavior and Overall Health in Children Aged 4-11 Years→Unflavored Powdered Multivitamin in Children
Oct 13, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Oct 13, 2026
    Title A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of an Unflavored Powdered Multivitamin on Behavior and Overall Health in Children Aged 4-11 Years→Unflavored Powdered Multivitamin in Children
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863050
Lead sponsor
EllaOla
Collaborators
People Science, Inc.
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 14, 2026 (estimated)
Primary completion
Mar 20, 2027 (estimated)
Completion
May 19, 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion